<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Australian Living Guideline for Inflammatory Arthritis</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Source+Sans+3:wght@300;400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    <style>
        :root {
            --primary-blue: #1e3a5f;
            --primary-teal: #0d9488;
            --primary-teal-light: #14b8a6;
            --primary-teal-dark: #0f766e;
            --accent-orange: #f59e0b;
            --text-dark: #1f2937;
            --text-medium: #4b5563;
            --text-light: #6b7280;
            --bg-cream: #fefdfb;
            --bg-light: #f8fafc;
            --bg-blue-light: #f0f9ff;
            --border-light: #e5e7eb;
            --border-medium: #d1d5db;
            --white: #ffffff;
            --shadow-md: 0 4px 6px -1px rgba(0,0,0,0.1);
            --shadow-lg: 0 10px 15px -3px rgba(0,0,0,0.1);
            --radius-sm: 6px;
            --radius-md: 10px;
            --radius-lg: 16px;
        }
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body {
            font-family: 'Source Sans 3', -apple-system, BlinkMacSystemFont, sans-serif;
            color: var(--text-dark);
            line-height: 1.6;
            background-color: var(--bg-cream);
        }
        /* HEADER */
        header {
            background: var(--white);
            border-bottom: 1px solid var(--border-light);
            position: sticky;
            top: 0;
            z-index: 1000;
        }
        .header-top {
            background: var(--primary-blue);
            padding: 8px 0;
        }
        .header-top-content {
            max-width: 1200px;
            margin: 0 auto;
            padding: 0 24px;
            display: flex;
            justify-content: flex-end;
            gap: 24px;
        }
        .header-top a {
            color: rgba(255,255,255,0.85);
            text-decoration: none;
            font-size: 13px;
            font-weight: 500;
        }
        .header-top a:hover { color: var(--white); }
        .header-main {
            max-width: 1200px;
            margin: 0 auto;
            padding: 16px 24px;
            display: flex;
            justify-content: space-between;
            align-items: center;
            flex-wrap: wrap;
            gap: 16px;
        }
        .logo-title {
            font-family: 'Source Serif 4', Georgia, serif;
            font-size: 22px;
            font-weight: 600;
            color: var(--primary-blue);
        }
        .logo-subtitle {
            font-size: 13px;
            color: var(--text-light);
        }
        nav { display: flex; gap: 8px; flex-wrap: wrap; }
        .nav-item { position: relative; }
        .nav-link {
            display: flex;
            align-items: center;
            gap: 6px;
            padding: 10px 16px;
            color: var(--text-medium);
            text-decoration: none;
            font-size: 15px;
            font-weight: 500;
            border-radius: var(--radius-sm);
            transition: all 0.2s;
        }
        .nav-link:hover {
            color: var(--primary-teal);
            background: var(--bg-light);
        }
        .nav-link svg { width: 14px; height: 14px; transition: transform 0.2s; }
        .nav-item:hover .nav-link svg { transform: rotate(180deg); }
        .dropdown {
            position: absolute;
            top: 100%;
            left: 0;
            min-width: 220px;
            background: var(--white);
            border-radius: var(--radius-md);
            box-shadow: var(--shadow-lg);
            border: 1px solid var(--border-light);
            opacity: 0;
            visibility: hidden;
            transform: translateY(10px);
            transition: all 0.2s;
            padding: 8px;
            z-index: 100;
        }
        .nav-item:hover .dropdown {
            opacity: 1;
            visibility: visible;
            transform: translateY(0);
        }
        .dropdown a {
            display: block;
            padding: 10px 14px;
            color: var(--text-medium);
            text-decoration: none;
            font-size: 14px;
            border-radius: var(--radius-sm);
        }
        .dropdown a:hover {
            background: var(--bg-light);
            color: var(--primary-teal);
        }
        /* HERO */
        .hero {
            background: linear-gradient(135deg, var(--primary-blue) 0%, #2d5a87 100%);
            padding: 80px 24px;
            position: relative;
        }
        .hero-content {
            max-width: 1200px;
            margin: 0 auto;
        }
        .hero h1 {
            font-family: 'Source Serif 4', Georgia, serif;
            font-size: clamp(28px, 5vw, 44px);
            font-weight: 600;
            color: var(--white);
            margin-bottom: 20px;
            max-width: 700px;
            line-height: 1.2;
        }
        .hero-description {
            font-size: 19px;
            color: rgba(255,255,255,0.9);
            max-width: 600px;
            line-height: 1.7;
            margin-bottom: 32px;
        }
        .hero-badges {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            margin-bottom: 32px;
        }
        .hero-badge {
            display: inline-flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: rgba(255,255,255,0.15);
            border-radius: 100px;
            color: var(--white);
            font-size: 14px;
            font-weight: 500;
        }
        .hero-badge svg { width: 16px; height: 16px; }
        .hero-cta {
            display: inline-flex;
            align-items: center;
            gap: 10px;
            padding: 14px 28px;
            background: var(--primary-teal);
            color: var(--white);
            text-decoration: none;
            font-size: 16px;
            font-weight: 600;
            border-radius: var(--radius-md);
            transition: all 0.2s;
            box-shadow: 0 4px 14px rgba(13,148,136,0.4);
        }
        .hero-cta:hover {
            background: var(--primary-teal-light);
            transform: translateY(-2px);
        }
        .hero-cta svg { width: 18px; height: 18px; }
        /* CONDITIONS SECTION */
        .conditions-section {
            padding: 60px 24px;
            background: var(--white);
        }
        .conditions-container {
            max-width: 1200px;
            margin: 0 auto;
        }
        .section-header {
            text-align: center;
            margin-bottom: 40px;
        }
        .section-header h2 {
            font-family: 'Source Serif 4', Georgia, serif;
            font-size: 32px;
            font-weight: 600;
            color: var(--primary-blue);
            margin-bottom: 12px;
        }
        .section-header p {
            font-size: 17px;
            color: var(--text-medium);
            max-width: 600px;
            margin: 0 auto;
        }
        .condition-tabs {
            display: flex;
            justify-content: center;
            gap: 8px;
            margin-bottom: 40px;
            flex-wrap: wrap;
        }
        .condition-tab {
            padding: 14px 28px;
            background: var(--bg-light);
            border: 2px solid transparent;
            border-radius: var(--radius-md);
            font-size: 15px;
            font-weight: 600;
            color: var(--text-medium);
            cursor: pointer;
            transition: all 0.2s;
        }
        .condition-tab:hover {
            border-color: var(--border-medium);
            color: var(--text-dark);
        }
        .condition-tab.active {
            background: var(--primary-teal);
            color: var(--white);
            border-color: var(--primary-teal);
        }
        /* RECOMMENDATION CARDS */
        .recommendations-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(340px, 1fr));
            gap: 24px;
        }
        .recommendation-card {
            background: var(--white);
            border: 1px solid var(--border-light);
            border-radius: var(--radius-lg);
            overflow: hidden;
            transition: all 0.3s;
            cursor: pointer;
        }
        .recommendation-card:hover {
            border-color: var(--primary-teal);
            box-shadow: var(--shadow-lg);
            transform: translateY(-4px);
        }
        .card-header {
            padding: 20px 24px;
            border-bottom: 1px solid var(--border-light);
            display: flex;
            justify-content: space-between;
            align-items: flex-start;
            gap: 16px;
        }
        .card-category {
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            color: var(--primary-teal);
            margin-bottom: 8px;
        }
        .card-title {
            font-family: 'Source Serif 4', Georgia, serif;
            font-size: 18px;
            font-weight: 600;
            color: var(--text-dark);
            line-height: 1.4;
        }
        .card-strength {
            flex-shrink: 0;
            display: flex;
            flex-direction: column;
            align-items: center;
            gap: 4px;
        }
        .strength-indicator {
            width: 48px;
            height: 48px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
        }
        .strength-indicator.strong-for {
            background: linear-gradient(135deg, var(--primary-teal) 0%, var(--primary-teal-dark) 100%);
        }
        .strength-indicator.conditional-for {
            background: linear-gradient(135deg, var(--accent-orange) 0%, #d97706 100%);
        }
        .strength-indicator.conditional-against {
            background: linear-gradient(135deg, #f87171 0%, #dc2626 100%);
        }
        .strength-indicator.strong-against {
            background: linear-gradient(135deg, #991b1b 0%, #7f1d1d 100%);
        }
        .strength-indicator svg {
            width: 24px;
            height: 24px;
            color: var(--white);
        }
        .strength-label {
            font-size: 10px;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.3px;
            color: var(--text-light);
            text-align: center;
        }
        .card-body { padding: 20px 24px; }
        .card-recommendation {
            font-size: 15px;
            color: var(--text-medium);
            line-height: 1.6;
            margin-bottom: 16px;
        }
        .card-tags {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }
        .card-tag {
            padding: 4px 10px;
            background: var(--bg-light);
            border-radius: 100px;
            font-size: 12px;
            font-weight: 500;
            color: var(--text-light);
        }
        .card-footer {
            padding: 16px 24px;
            background: var(--bg-light);
            display: flex;
            justify-content: space-between;
            align-items: center;
        }
        .card-link {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            color: var(--primary-teal);
            text-decoration: none;
            font-size: 14px;
            font-weight: 600;
        }
        .card-link:hover { gap: 10px; }
        .card-link svg { width: 16px; height: 16px; }
        .card-updated {
            font-size: 12px;
            color: var(--text-light);
        }
        /* MODAL */
        .modal-overlay {
            position: fixed;
            top: 0; left: 0; right: 0; bottom: 0;
            background: rgba(0,0,0,0.5);
            z-index: 2000;
            display: none;
            align-items: center;
            justify-content: center;
            padding: 24px;
            backdrop-filter: blur(4px);
        }
        .modal-overlay.active { display: flex; }
        .modal-content {
            background: var(--white);
            border-radius: var(--radius-lg);
            max-width: 900px;
            width: 100%;
            max-height: 90vh;
            overflow: hidden;
            display: flex;
            flex-direction: column;
            box-shadow: 0 25px 50px -12px rgba(0,0,0,0.25);
        }
        .modal-header {
            padding: 24px 32px;
            border-bottom: 1px solid var(--border-light);
            display: flex;
            justify-content: space-between;
            align-items: flex-start;
            gap: 20px;
        }
        .modal-category {
            font-size: 13px;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            color: var(--primary-teal);
            margin-bottom: 8px;
        }
        .modal-title {
            font-family: 'Source Serif 4', Georgia, serif;
            font-size: 24px;
            font-weight: 600;
            color: var(--text-dark);
            line-height: 1.3;
        }
        .modal-close {
            width: 40px; height: 40px;
            border: none;
            background: var(--bg-light);
            border-radius: 50%;
            cursor: pointer;
            display: flex;
            align-items: center;
            justify-content: center;
            flex-shrink: 0;
        }
        .modal-close:hover { background: var(--border-light); }
        .modal-close svg { width: 20px; height: 20px; color: var(--text-medium); }
        .modal-tabs {
            display: flex !important;
            flex-wrap: wrap;
            padding: 0 32px;
            border-bottom: 1px solid var(--border-light);
            background: var(--bg-light);
            overflow-x: auto;
            min-height: 50px;
        }
        .modal-tab {
            padding: 16px 20px;
            font-size: 14px;
            font-weight: 600;
            color: var(--text-light);
            cursor: pointer;
            border-bottom: 3px solid transparent;
            margin-bottom: -1px;
            white-space: nowrap;
            background: none;
            border-top: none;
            border-left: none;
            border-right: none;
        }
        .modal-tab:hover { color: var(--text-medium); background: rgba(0,0,0,0.02); }
        .modal-tab.active {
            color: var(--primary-teal);
            border-bottom-color: var(--primary-teal);
            background: var(--white);
        }
        .modal-body {
            padding: 32px;
            overflow-y: auto;
            flex: 1;
        }
        .tab-content { display: none; }
        .tab-content.active { display: block; }
        .recommendation-box {
            background: var(--bg-blue-light);
            border-left: 5px solid var(--primary-teal);
            padding: 24px 28px;
            border-radius: 0 var(--radius-md) var(--radius-md) 0;
            margin-bottom: 24px;
        }
        .recommendation-box p {
            font-family: 'Source Serif 4', Georgia, serif;
            font-size: 19px;
            font-weight: 600;
            color: var(--primary-blue);
            line-height: 1.6;
        }
        .remark-box {
            background: var(--bg-light);
            padding: 16px 20px;
            border-radius: var(--radius-md);
            margin-bottom: 24px;
            border: 1px solid var(--border-light);
        }
        .remark-box p {
            font-size: 15px;
            color: var(--text-medium);
            line-height: 1.7;
            font-style: italic;
        }
        .strength-badge {
            display: inline-flex;
            align-items: center;
            gap: 8px;
            padding: 8px 14px;
            border-radius: 100px;
            font-size: 13px;
            font-weight: 600;
            margin-bottom: 20px;
        }
        .strength-badge.conditional-for {
            background: rgba(245,158,11,0.1);
            color: #b45309;
        }
        .strength-badge.strong-for {
            background: rgba(13,148,136,0.1);
            color: var(--primary-teal-dark);
        }
        .content-section { margin-bottom: 28px; }
        .content-section:last-child { margin-bottom: 0; }
        .content-section h3 {
            font-size: 16px;
            font-weight: 600;
            color: var(--text-dark);
            margin-bottom: 12px;
        }
        .content-section h4 {
            font-size: 15px;
            font-weight: 600;
            color: var(--text-dark);
            margin-bottom: 8px;
            margin-top: 16px;
        }
        .content-section p, .content-section li {
            font-size: 15px;
            color: var(--text-medium);
            line-height: 1.7;
        }
        .content-section ul { padding-left: 20px; margin-top: 8px; }
        .content-section li { margin-bottom: 8px; }
        .content-section a {
            color: var(--primary-teal);
            text-decoration: underline;
        }
        .content-section a:hover {
            color: var(--primary-teal-dark);
        }
        /* EtD Domain styling */
        .etd-domain {
            margin-bottom: 24px;
            padding: 20px;
            background: var(--bg-light);
            border-radius: var(--radius-md);
            border: 1px solid var(--border-light);
        }
        .etd-domain:last-child { margin-bottom: 0; }
        .etd-domain-header {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-bottom: 12px;
            flex-wrap: wrap;
            gap: 8px;
        }
        .etd-domain-title {
            font-size: 16px;
            font-weight: 600;
            color: var(--text-dark);
        }
        .etd-rating {
            display: inline-block;
            padding: 4px 12px;
            background: var(--white);
            border: 1px solid var(--border-medium);
            border-radius: 100px;
            font-size: 12px;
            font-weight: 600;
            color: var(--text-medium);
        }
        .etd-domain-text {
            font-size: 14px;
            color: var(--text-medium);
            line-height: 1.7;
        }
        .etd-domain-text ul {
            padding-left: 20px;
            margin-top: 8px;
        }
        .etd-domain-text li {
            margin-bottom: 6px;
        }
        .modal-footer {
            padding: 20px 32px;
            border-top: 1px solid var(--border-light);
            display: flex;
            justify-content: space-between;
            align-items: center;
            background: var(--bg-light);
            flex-wrap: wrap;
            gap: 16px;
        }
        .magicapp-link {
            display: inline-flex;
            align-items: center;
            gap: 8px;
            padding: 12px 20px;
            background: var(--primary-blue);
            color: var(--white);
            text-decoration: none;
            font-size: 14px;
            font-weight: 600;
            border-radius: var(--radius-md);
        }
        .magicapp-link:hover { background: #2d5a87; }
        .magicapp-link svg { width: 16px; height: 16px; }
        /* Data tab placeholder */
        .data-placeholder {
            text-align: center;
            padding: 40px;
            background: var(--bg-light);
            border-radius: var(--radius-md);
            border: 2px dashed var(--border-medium);
        }
        .data-placeholder p {
            color: var(--text-light);
            font-size: 15px;
        }
        /* ABOUT SECTION */
        .about-section {
            padding: 80px 24px;
            background: var(--bg-light);
        }
        .about-container {
            max-width: 1200px;
            margin: 0 auto;
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 60px;
            align-items: center;
        }
        .about-content h2 {
            font-family: 'Source Serif 4', Georgia, serif;
            font-size: 32px;
            font-weight: 600;
            color: var(--primary-blue);
            margin-bottom: 20px;
        }
        .about-content p {
            font-size: 16px;
            color: var(--text-medium);
            line-height: 1.8;
            margin-bottom: 16px;
        }
        .about-features {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 20px;
        }
        .feature-card {
            padding: 24px;
            background: var(--white);
            border-radius: var(--radius-md);
            border: 1px solid var(--border-light);
        }
        .feature-icon {
            width: 48px; height: 48px;
            background: linear-gradient(135deg, var(--primary-teal) 0%, var(--primary-teal-dark) 100%);
            border-radius: var(--radius-md);
            display: flex;
            align-items: center;
            justify-content: center;
            margin-bottom: 16px;
        }
        .feature-icon svg { width: 24px; height: 24px; color: var(--white); }
        .feature-card h3 {
            font-size: 16px;
            font-weight: 600;
            color: var(--text-dark);
            margin-bottom: 8px;
        }
        .feature-card p {
            font-size: 14px;
            color: var(--text-light);
            line-height: 1.6;
            margin: 0;
        }
        /* PARTNERS */
        .partners-section {
            padding: 60px 24px;
            background: var(--white);
            border-top: 1px solid var(--border-light);
        }
        .partners-container {
            max-width: 1200px;
            margin: 0 auto;
            text-align: center;
        }
        .partners-label {
            font-size: 13px;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 1px;
            color: var(--text-light);
            margin-bottom: 24px;
        }
        .partners-logos {
            display: flex;
            justify-content: center;
            align-items: center;
            gap: 32px;
            flex-wrap: wrap;
        }
        .partner-text {
            font-size: 14px;
            font-weight: 600;
            color: var(--text-light);
            padding: 12px 20px;
            border: 1px solid var(--border-light);
            border-radius: var(--radius-sm);
        }
        /* FOOTER */
        footer {
            background: var(--primary-blue);
            padding: 60px 24px 30px;
            color: var(--white);
        }
        .footer-container { max-width: 1200px; margin: 0 auto; }
        .footer-grid {
            display: grid;
            grid-template-columns: 2fr 1fr 1fr 1fr;
            gap: 48px;
            margin-bottom: 48px;
        }
        .footer-brand h3 {
            font-family: 'Source Serif 4', Georgia, serif;
            font-size: 20px;
            font-weight: 600;
            margin-bottom: 16px;
        }
        .footer-brand p {
            font-size: 14px;
            color: rgba(255,255,255,0.7);
            line-height: 1.7;
        }
        .footer-column h4 {
            font-size: 14px;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            margin-bottom: 16px;
        }
        .footer-column a {
            display: block;
            color: rgba(255,255,255,0.7);
            text-decoration: none;
            font-size: 14px;
            padding: 6px 0;
        }
        .footer-column a:hover { color: var(--white); }
        .footer-bottom {
            padding-top: 30px;
            border-top: 1px solid rgba(255,255,255,0.1);
            display: flex;
            justify-content: space-between;
            align-items: center;
            flex-wrap: wrap;
            gap: 16px;
        }
        .footer-copyright {
            font-size: 13px;
            color: rgba(255,255,255,0.5);
        }
        .footer-links { display: flex; gap: 24px; }
        .footer-links a {
            color: rgba(255,255,255,0.5);
            text-decoration: none;
            font-size: 13px;
        }
        .footer-links a:hover { color: var(--white); }
        /* RESPONSIVE */
        @media (max-width: 1024px) {
            .about-container { grid-template-columns: 1fr; gap: 40px; }
            .footer-grid { grid-template-columns: 1fr 1fr; }
        }
        @media (max-width: 768px) {
            .recommendations-grid { grid-template-columns: 1fr; }
            .about-features { grid-template-columns: 1fr; }
            .footer-grid { grid-template-columns: 1fr; gap: 32px; }
            .modal-content { max-height: 100vh; border-radius: 0; }
            .modal-header, .modal-body, .modal-footer { padding-left: 20px; padding-right: 20px; }
        }
    </style>
</head>
<body>
    <!-- HEADER -->
    <header>
        <div class="header-top">
            <div class="header-top-content">
                <a href="https://anzmusc.org" target="_blank">ANZMUSC</a>
                <a href="https://rheumatology.org.au" target="_blank">Australian Rheumatology Association</a>
                <a href="https://musculoskeletal.cochrane.org" target="_blank">Cochrane Musculoskeletal</a>
            </div>
        </div>
        <div class="header-main">
            <div class="logo">
                <div class="logo-title">Australian Living Guideline</div>
                <div class="logo-subtitle">Pharmacological Management of Inflammatory Arthritis</div>
            </div>
            <nav>
                <div class="nav-item">
                    <a href="#" class="nav-link">
                        About
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.23 7.21a.75.75 0 011.06.02L10 11.168l3.71-3.938a.75.75 0 111.08 1.04l-4.25 4.5a.75.75 0 01-1.08 0l-4.25-4.5a.75.75 0 01.02-1.06z" clip-rule="evenodd"/></svg>
                    </a>
                    <div class="dropdown">
                        <a href="#">How to Use This Guideline</a>
                        <a href="#">Who We Are</a>
                        <a href="#">Methodology</a>
                        <a href="#">Funding & Support</a>
                        <a href="#">Conflicts of Interest</a>
                    </div>
                </div>
                <div class="nav-item">
                    <a href="#" class="nav-link">
                        Resources
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.23 7.21a.75.75 0 011.06.02L10 11.168l3.71-3.938a.75.75 0 111.08 1.04l-4.25 4.5a.75.75 0 01-1.08 0l-4.25-4.5a.75.75 0 01.02-1.06z" clip-rule="evenodd"/></svg>
                    </a>
                    <div class="dropdown">
                        <a href="#">Glossary</a>
                        <a href="#">Abbreviations</a>
                        <a href="#">External Links</a>
                        <a href="#">Consumer Information</a>
                    </div>
                </div>
                <a href="#recommendations" class="nav-link">Recommendations</a>
                <a href="#" class="nav-link">Contact</a>
            </nav>
        </div>
    </header>

    <!-- HERO -->
    <section class="hero">
        <div class="hero-content">
            <h1>Evidence-based guidance for inflammatory arthritis treatment</h1>
            <p class="hero-description">Helping Australian clinicians and patients make informed decisions about the pharmacological management of rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.</p>
            <div class="hero-badges">
                <span class="hero-badge">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M16.403 12.652a3 3 0 000-5.304 3 3 0 00-3.75-3.751 3 3 0 00-5.305 0 3 3 0 00-3.751 3.75 3 3 0 000 5.305 3 3 0 003.75 3.751 3 3 0 005.305 0 3 3 0 003.751-3.75zm-2.546-4.46a.75.75 0 00-1.214-.883l-3.483 4.79-1.88-1.88a.75.75 0 10-1.06 1.061l2.5 2.5a.75.75 0 001.137-.089l4-5.5z" clip-rule="evenodd"/></svg>
                    NHMRC Approved
                </span>
                <span class="hero-badge">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm.75-13a.75.75 0 00-1.5 0v5c0 .414.336.75.75.75h4a.75.75 0 000-1.5h-3.25V5z" clip-rule="evenodd"/></svg>
                    Living Guideline
                </span>
                <span class="hero-badge">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg>
                    ~20 Recommendations
                </span>
            </div>
            <a href="#recommendations" class="hero-cta">
                Browse Recommendations
                <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M2 10a.75.75 0 01.75-.75h12.59l-2.1-1.95a.75.75 0 111.02-1.1l3.5 3.25a.75.75 0 010 1.1l-3.5 3.25a.75.75 0 11-1.02-1.1l2.1-1.95H2.75A.75.75 0 012 10z" clip-rule="evenodd"/></svg>
            </a>
        </div>
    </section>

    <!-- RECOMMENDATIONS -->
    <section class="conditions-section" id="recommendations">
        <div class="conditions-container">
            <div class="section-header">
                <h2>Recommendations by Condition</h2>
                <p>Select a condition to view relevant treatment recommendations, or browse all recommendations below.</p>
            </div>
            <div class="condition-tabs">
                <button class="condition-tab active" data-condition="all">All Recommendations</button>
                <button class="condition-tab" data-condition="ra">Rheumatoid Arthritis</button>
                <button class="condition-tab" data-condition="psa">Psoriatic Arthritis</button>
                <button class="condition-tab" data-condition="axspa">Axial Spondyloarthritis</button>
            </div>
            <div class="recommendations-grid">
                <!-- Card 1: Initial DMARD Therapy (REAL CONTENT) -->
                <div class="recommendation-card" data-conditions="ra" onclick="openModal('initial-dmard')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Initial DMARD Therapy</div>
                            <div class="card-title">Initial DMARD therapy for people with rheumatoid arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for">
                                <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg>
                            </div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Consider using methotrexate in combination with other DMARDs as initial therapy in people with rheumatoid arthritis.</p>
                        <div class="card-tags">
                            <span class="card-tag">Methotrexate</span>
                            <span class="card-tag">Triple therapy</span>
                            <span class="card-tag">DMARD-naïve</span>
                        </div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
                <!-- Card 2: Placeholder -->
                <div class="recommendation-card" data-conditions="ra" onclick="openModal('placeholder')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Route of Administration</div>
                            <div class="card-title">Oral versus subcutaneous methotrexate</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for">
                                <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg>
                            </div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">We conditionally recommend oral administration for people with rheumatoid arthritis who are commencing methotrexate.</p>
                        <div class="card-tags">
                            <span class="card-tag">Methotrexate</span>
                            <span class="card-tag">Administration</span>
                        </div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
                <!-- Card 3: Placeholder -->
                <div class="recommendation-card" data-conditions="ra" onclick="openModal('placeholder')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Switching Therapy</div>
                            <div class="card-title">DMARD choice after inadequate response to TNF inhibitor</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for">
                                <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg>
                            </div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Consider switching therapy to an alternative b/tsDMARD – either a different TNFi or a b/tsDMARD with a different mechanism of action.</p>
                        <div class="card-tags">
                            <span class="card-tag">bDMARD</span>
                            <span class="card-tag">TNF inhibitor</span>
                        </div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
                <!-- Card 4: Placeholder -->
                <div class="recommendation-card" data-conditions="ra psa axspa" onclick="openModal('placeholder')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Perioperative Management</div>
                            <div class="card-title">csDMARDs in the perioperative period</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for">
                                <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg>
                            </div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Do not routinely discontinue csDMARDs in the perioperative period.</p>
                        <div class="card-tags">
                            <span class="card-tag">Surgery</span>
                            <span class="card-tag">csDMARD</span>
                        </div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
                <!-- Card 5: Placeholder -->
                <div class="recommendation-card" data-conditions="ra psa axspa" onclick="openModal('placeholder')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Perioperative Management</div>
                            <div class="card-title">bDMARDs in the perioperative period</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for">
                                <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg>
                            </div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Do not routinely discontinue bDMARDs in the perioperative period; consider temporary discontinuation in high-risk individuals.</p>
                        <div class="card-tags">
                            <span class="card-tag">Surgery</span>
                            <span class="card-tag">bDMARD</span>
                        </div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
                <!-- Card 6: Placeholder -->
                <div class="recommendation-card" data-conditions="axspa" onclick="openModal('placeholder')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Down-titration</div>
                            <div class="card-title">bDMARD dose reduction in axial spondyloarthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for">
                                <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg>
                            </div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In people with axSpA in sustained low disease activity or remission for at least 6 months, consider reduction in the dose of bDMARD.</p>
                        <div class="card-tags">
                            <span class="card-tag">bDMARD</span>
                            <span class="card-tag">Remission</span>
                        </div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <!-- ABOUT -->
    <section class="about-section">
        <div class="about-container">
            <div class="about-content">
                <h2>About This Living Guideline</h2>
                <p>This guideline presents the best available, current scientific evidence for pharmacological management of the most common forms of inflammatory arthritis: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA).</p>
                <p>As a living guideline, recommendations are updated in near real-time as new evidence emerges. Topics and questions identified as having highest clinical relevance are prioritised, including DMARD choice, switching, combination therapy, down-titration, and perioperative use.</p>
            </div>
            <div class="about-features">
                <div class="feature-card">
                    <div class="feature-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm.75-13a.75.75 0 00-1.5 0v5c0 .414.336.75.75.75h4a.75.75 0 000-1.5h-3.25V5z" clip-rule="evenodd"/></svg></div>
                    <h3>Living Evidence</h3>
                    <p>Recommendations updated as new practice-changing evidence becomes available.</p>
                </div>
                <div class="feature-card">
                    <div class="feature-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M16.403 12.652a3 3 0 000-5.304 3 3 0 00-3.75-3.751 3 3 0 00-5.305 0 3 3 0 00-3.751 3.75 3 3 0 000 5.305 3 3 0 003.75 3.751 3 3 0 005.305 0 3 3 0 003.751-3.75zm-2.546-4.46a.75.75 0 00-1.214-.883l-3.483 4.79-1.88-1.88a.75.75 0 10-1.06 1.061l2.5 2.5a.75.75 0 001.137-.089l4-5.5z" clip-rule="evenodd"/></svg></div>
                    <h3>GRADE Methodology</h3>
                    <p>Rigorous evidence assessment using internationally recognised standards.</p>
                </div>
                <div class="feature-card">
                    <div class="feature-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg></div>
                    <h3>Expert Panel</h3>
                    <p>Developed by rheumatologists, researchers, and consumer representatives.</p>
                </div>
                <div class="feature-card">
                    <div class="feature-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3.505 2.365A41.369 41.369 0 019 2c1.863 0 3.697.124 5.495.365 1.247.167 2.18 1.108 2.435 2.268a4.45 4.45 0 00-.577-.069 43.141 43.141 0 00-4.706 0C9.229 4.696 7.5 6.727 7.5 8.998v2.24c0 1.413.67 2.735 1.76 3.562l-2.98 2.98A.75.75 0 015 17.25v-3.443c-.501-.048-1-.106-1.495-.172C2.033 13.438 1 12.162 1 10.72V5.28c0-1.441 1.033-2.717 2.505-2.914z"/><path d="M14 6c-.762 0-1.52.02-2.271.062C10.157 6.148 9 7.472 9 8.998v2.24c0 1.519 1.147 2.839 2.71 2.935.214.013.428.024.642.034.2.009.385.09.518.224l2.35 2.35a.75.75 0 001.28-.531v-2.07c1.453-.195 2.5-1.463 2.5-2.915V8.998c0-1.526-1.157-2.85-2.729-2.936A41.645 41.645 0 0014 6z"/></svg></div>
                    <h3>Shared Decision Making</h3>
                    <p>Supporting informed discussions between clinicians and patients.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- PARTNERS -->
    <section class="partners-section">
        <div class="partners-container">
            <div class="partners-label">Produced in collaboration with</div>
            <div class="partners-logos">
                <span class="partner-text">ANZMUSC</span>
                <span class="partner-text">Australian Rheumatology Association</span>
                <span class="partner-text">Cochrane Musculoskeletal</span>
            </div>
        </div>
    </section>

    <!-- FOOTER -->
    <footer>
        <div class="footer-container">
            <div class="footer-grid">
                <div class="footer-brand">
                    <h3>Australian Living Guideline for Inflammatory Arthritis</h3>
                    <p>Evidence-based recommendations for the pharmacological management of rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.</p>
                </div>
                <div class="footer-column">
                    <h4>Guideline</h4>
                    <a href="#">All Recommendations</a>
                    <a href="#">Rheumatoid Arthritis</a>
                    <a href="#">Psoriatic Arthritis</a>
                    <a href="#">Axial Spondyloarthritis</a>
                </div>
                <div class="footer-column">
                    <h4>Resources</h4>
                    <a href="#">How to Use</a>
                    <a href="#">Glossary</a>
                    <a href="#">Abbreviations</a>
                    <a href="#">External Links</a>
                </div>
                <div class="footer-column">
                    <h4>About</h4>
                    <a href="#">Who We Are</a>
                    <a href="#">Methodology</a>
                    <a href="#">Funding</a>
                    <a href="#">Contact</a>
                </div>
            </div>
            <div class="footer-bottom">
                <div class="footer-copyright">© 2024 ANZMUSC Clinical Trials Network. All rights reserved.</div>
                <div class="footer-links">
                    <a href="#">Privacy Policy</a>
                    <a href="#">Disclaimer</a>
                    <a href="#">Accessibility</a>
                </div>
            </div>
        </div>
    </footer>

    <!-- MODAL: Initial DMARD Therapy (FULL CONTENT) -->
    <div class="modal-overlay" id="modal-initial-dmard">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Initial DMARD Therapy</div>
                    <h2 class="modal-title">Initial DMARD therapy for people with rheumatoid arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg>
                </button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('initial-dmard', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('initial-dmard', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('initial-dmard', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('initial-dmard', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('initial-dmard', 'consumer')">For Consumers</button>
            </div>
            <div class="modal-body">
                <!-- Recommendation Tab -->
                <div class="tab-content active" id="initial-dmard-recommendation">
                    <span class="strength-badge conditional-for">⊕ Conditional Recommendation For</span>
                    
                    <div class="recommendation-box">
                        <p>Consider using methotrexate in combination with other DMARDs as initial therapy in people with rheumatoid arthritis.</p>
                    </div>
                    
                    <div class="remark-box">
                        <p>For most people this implies triple therapy (methotrexate + sulfasalazine + hydroxychloroquine). While the combination of methotrexate and most b/tsDMARDs is also effective, this is currently not a feasible option for most people.</p>
                    </div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>For this recommendation, the panel only considered the choice of methotrexate (MTX) monotherapy versus MTX combination therapy as the initial choice of treatment in people with RA who have not previously received any DMARDs. The panel did not consider the choice of DMARD in people with RA who have used MTX and had an inadequate response or have been unable to tolerate it; this will form a separate future recommendation.</p>
                        
                        <p>The panel was satisfied that MTX remains the anchor drug for RA and should remain part of the initial treatment regimen for most people with RA. As such, a network meta-analysis that compared MTX monotherapy to MTX-based combination therapies was used as the primary evidence source for this recommendation, supplemented by two subsequent RCTs of MTX monotherapy versus MTX in combination with JAK inhibitors that also would have met the inclusion criteria for the original NMA. We are currently completing a new living NMA of all DMARDs for the treatment of RA which will become available in 2024 and will form the ongoing evidence base for updates to this living recommendation.</p>
                        
                        <p>The panel did not consider other forms of monotherapy (eg hydroxychloroquine) although it recognised that there may be some clinical circumstances (e.g., very mild disease, or a contraindication to MTX) in which clinicians may choose another csDMARD as initial monotherapy. The panel elected to consider all forms of combination DMARD therapy, including combinations of MTX with bDMARDs or tsDMARDs, although the panel acknowledges that b/tsDMARDs are far more expensive than csDMARDs and are not currently subsidised for this indication in Australia.</p>
                        
                        <p>Furthermore, the NMA that formed the evidence base for this recommendation did not demonstrate a difference in efficacy between 'triple therapy' (MTX, sulfasalazine and hydroxychloroquine) and any b/tsDMARD in combination with MTX. Therefore the panel considered that, in practice, initial therapy with b/tsDMARDs is rarely practical or necessary, but the recommendation allows for the possibility that some individuals may choose such a combination in certain clinical circumstances and where finances permit.</p>
                        
                        <p>Importantly, the panel limited discussion to the initial choice of DMARD and did not consider the role of DMARD strategies (such as sequential monotherapy versus step-up combination therapy). The potential benefits and harms of different DMARD strategies will be considered in light of future recommendations regarding the management of people with RA who have had an inadequate response to the initial DMARD therapy. Regardless of the choice of DMARD, the panel emphasised the importance of a treat-to-target approach to the treatment of RA.</p>
                        
                        <p>The panel based the recommendation on moderate certainty evidence from the NMA that triple therapy is superior to MTX monotherapy for the primary efficacy outcome (ACR50) and has similar tolerability and safety compared with MTX monotherapy. The panel discussed the concern that initial triple therapy might be an excessively complex or daunting medication regimen for those newly-diagnosed with RA, but the consumer panellist noted that MTX is often the DMARD that causes the most initial concern for people with RA and that additional DMARDs are often acceptable once a decision to take MTX has been made. In addition, the panel considered evidence that suggests that many consumers favour initial combination therapy over MTX monotherapy.</p>
                        
                        <p>The panel noted that triple therapy was the only csDMARD combination that was found to have superior efficacy compared with MTX monotherapy. The combination of MTX with one other DMARD (e.g., hydroxychloroquine or sulfasalazine) has not been shown to be superior to MTX monotherapy as the initial treatment for RA and therefore those who elect to commence combination csDMARD therapy should choose triple therapy.</p>
                        
                        <p>The panel also emphasised that the recommendation is conditional and that there is likely to be a considerable difference in preferences between individuals. While many people with RA may prefer the potential benefits of initial triple therapy (at the expense of a higher medication burden than MTX monotherapy), some patients may prefer a simpler initial regimen in the knowledge that treatment outcomes and the choice of DMARD therapy are frequently reviewed in a treat-to-target paradigm. On average, there is a modest net benefit associated with combination therapy versus MTX monotherapy but the magnitude or impact of this benefit is likely to vary between patients.</p>
                        
                        <p>While a variety of treatment strategies are likely to be effective for RA when employed within a treat-to-target approach, there may be some differences in the speed at which the target disease activity state is achieved, and this may be an important consideration for some people, depending on their individual circumstances. Many factors are likely to be considered in the initial choice of DMARD treatment, including the individual treatment goals, preferences, values, comorbidities and concurrent medications, disease activity and prognosis, functional status, work and other life roles.</p>
                    </div>
                </div>

                <!-- Evidence to Decision Tab -->
                <div class="tab-content" id="initial-dmard-etd">
                    <div class="etd-domain">
                        <div class="etd-domain-header">
                            <span class="etd-domain-title">Benefits and Harms</span>
                            <span class="etd-rating">Small net benefit, or little difference between alternatives</span>
                        </div>
                        <div class="etd-domain-text">
                            <p>The evidence considered by the panel for this recommendation specifically relates to the choice of methotrexate monotherapy versus methotrexate in combination with (one or more) other DMARDs as the initial therapy in people with rheumatoid arthritis (RA) who have not previously used DMARDs. The evidence is primarily drawn from a Cochrane systematic review and network meta-analysis of 93 studies in DMARD-naive participants, and two RCTs published subsequently.</p>
                            
                            <p><strong>Compared to MTX oral monotherapy:</strong></p>
                            <ul>
                                <li>Several treatment combinations with methotrexate resulted in a better ACR50 response rate: methotrexate + sulfasalazine + hydroxychloroquine ('triple therapy'), methotrexate + several biologics (abatacept, adalimumab, etanercept, infliximab, rituximab, tocilizumab), and methotrexate + tofacitinib. The estimated probability of ACR50 response was similar between these treatments (range 56-67%), compared with 41% for methotrexate alone.</li>
                                <li>ACR50 response rate was similar in people receiving 'triple therapy' (methotrexate + sulfasalazine + hydroxychloroquine) and in those receiving methotrexate + b/tsDMARDs.</li>
                                <li>Radiographic progression was similar in people receiving triple therapy and methotrexate monotherapy. Compared with methotrexate alone, methotrexate combined with adalimumab, etanercept, certolizumab, or infliximab slowed radiographic progression slightly (but less than the minimal clinically important difference of five units on the Sharp-van der Heijde scale over 1 year).</li>
                                <li>Withdrawals due to adverse events were similar in people receiving triple therapy compared with those receiving methotrexate monotherapy. Methotrexate + azathioprine had more withdrawals due to adverse events compared with methotrexate monotherapy, and triple therapy had fewer withdrawals due to adverse events than methotrexate + infliximab.</li>
                            </ul>
                            <p>The panel elected to vote on the benefits and harms of MTX monotherapy vs all MTX-based combinations (including combination therapy with b/tsDMARDs that are not currently PBS-subsidised in Australia for initial therapy) but noted that, in practice, the available choices for Australian patients are limited to combinations of csDMARDs.</p>
                        </div>
                    </div>

                    <div class="etd-domain">
                        <div class="etd-domain-header">
                            <span class="etd-domain-title">Certainty of the Evidence</span>
                            <span class="etd-rating">Moderate</span>
                        </div>
                        <div class="etd-domain-text">
                            <p>For treatment response (measured by ACR50), evidence was moderate certainty for csDMARD triple therapy versus methotrexate monotherapy (downgraded for indirectness), and moderate or high certainty for most other comparisons.</p>
                            <p>For radiographic progression and withdrawals due to adverse events, evidence was moderate certainty for csDMARD triple therapy versus methotrexate monotherapy (downgraded for imprecision), and low to moderate certainty for most other comparisons.</p>
                            <p><strong>There are some limitations in applicability of the evidence, including the following:</strong></p>
                            <ul>
                                <li>The effect of glucocorticoid therapy in addition to DMARDs was not assessed</li>
                                <li>The analysis did not directly compare the strategy of starting with methotrexate monotherapy in methotrexate-naïve patients and progressing to triple therapy versus the strategy of starting with triple therapy from the outset</li>
                                <li>MTX combination therapies with newer b/tsDMARDs are not included in the evidence here (such trials will be captured in a new systematic review and network meta-analysis currently underway)</li>
                                <li>Adverse event data are limited to events likely to be reported in RCTs; potential rare long term adverse events are best captured within registries and do not form part of this evidence base</li>
                            </ul>
                        </div>
                    </div>

                    <div class="etd-domain">
                        <div class="etd-domain-header">
                            <span class="etd-domain-title">Values and Preferences</span>
                            <span class="etd-rating">Substantial variability is expected or uncertain</span>
                        </div>
                        <div class="etd-domain-text">
                            <p>A recent systematic review of patient preferences for DMARD treatment in RA included 36 studies published between 1990 and 2018, although the included studies generally involved those who had already commenced DMARDs and only two studies involved participants with early RA (i.e., those who are most likely to be making decisions about the initial choice of DMARD). The review found that, in general, people with RA consider treatment benefits (particularly improvement in symptoms and function) to be more important than both serious and non-serious adverse events (AEs). However some studies found evidence of important risk aversion (particularly regarding serious AEs), which suggests that there is considerable variation in preferences between individuals. Dosing and administration considerations, including route and frequency of medications, were generally found to be less important than treatment benefits but more important than AEs, although this also varied between and within studies. Overall, the results suggest that individual preferences are likely to be an important factor in shared decision-making regarding treatments for RA.</p>
                            <p>A study of 152 patients with early RA (&lt;2 years since diagnosis) that used a discrete-choice experiment design also identified important heterogeneity in preferences. In general, treatment benefits were considered the most important treatment attribute, however latent-class analysis also identified that approximately half of the patients were more risk averse (particularly to serious adverse effects) in comparison to the other half who were more benefit-driven. In this study sample, participants would be willing to tolerate an increase in pill burden (triple therapy versus weekly oral medication) for a relatively small increment in treatment benefits (&lt;5% absolute increase in chance of major symptom improvement), although the incremental improvement required was considerably higher for those in the risk averse group.</p>
                            <p>The panel considered that while many people would be likely to choose the treatment regimen that offers the highest chance of improving their current symptoms (including pain), there was also evidence that there is likely to be substantial variability between individuals in their preferences and values.</p>
                        </div>
                    </div>

                    <div class="etd-domain">
                        <div class="etd-domain-header">
                            <span class="etd-domain-title">Resources</span>
                            <span class="etd-rating">Important issues, or potential issues not investigated</span>
                        </div>
                        <div class="etd-domain-text">
                            <p>We have not systematically reviewed the cost-effectiveness of methotrexate monotherapy versus combination therapy in DMARD-naïve patients with rheumatoid arthritis. There is some evidence that the use of triple therapy as the initial therapy is more cost-effective than initial therapy with methotrexate monotherapy in people with very early inflammatory arthritis in a European setting, although the estimates in this population (in which relatively large doses of glucocorticoids were used as an adjunct to csDMARDs) may not apply to the current Australian context.</p>
                            <p>Although there are no publicly available data regarding the actual comparative costs of different bDMARDs to the payer (i.e. the Federal Government) in Australia, b/tsDMARDs are generally far more expensive than csDMARDs and therefore the cost implications of b/tsDMARD use are likely to be an important consideration at the societal level and for funders, particularly if there are marginal differences in efficacy.</p>
                            <p>At the individual patient level the direct cost implications are less profound for those who meet Government funding criteria, however currently DMARD-naïve patients with RA are not eligible for subsidised treatment with any b/tsDMARD in Australia. The impact of prescription dispensing fees may be higher for those using combination csDMARDs versus monotherapy, although the absolute cost difference and its impact is likely to vary between individual patients.</p>
                            <p>We did not identify any data regarding the impact of methotrexate monotherapy versus combination therapy with csDMARDs or b/tsDMARDs on the environment. It is plausible that combination therapy (particularly with bDMARDs) may have a larger negative impact on the environment due to manufacturing, packaging and transport, however the magnitude of such an impact (if present) or other indirect effects is currently unknown.</p>
                            <p>The panel discussed the implications of the large cost difference between csDMARDs and b/tsDMARDs. The cost implications of MTX monotherapy versus combination therapy with csDMARDs are likely to be small, but the current cost of b/tsDMARDs would have a major impact on their potential use as an initial therapy for RA.</p>
                        </div>
                    </div>

                    <div class="etd-domain">
                        <div class="etd-domain-header">
                            <span class="etd-domain-title">Equity</span>
                            <span class="etd-rating">Important issues, or potential issues not investigated</span>
                        </div>
                        <div class="etd-domain-text">
                            <p>There are a number of factors that may influence the health opportunities and outcomes in individual patients. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may be important considerations in the choice of initial DMARD therapy, particularly DMARD regimens that involve complex dosing, regular dose adjustments, or frequent monitoring for adverse effects, and as a result may have an impact on equity if the opportunity to access initial combination therapy varies between groups.</p>
                            <p>The panel noted the importance of access to a rheumatologist. It considered that while some other practitioners (e.g., GPs, general physicians) may consider prescription of csDMARD monotherapy for people with early RA who are unable to promptly access a rheumatologist, initial combination therapy is likely to require more specialist expertise. As such, people who are less able to access immediate specialist care may be less likely to receive combination therapy.</p>
                            <p>The panel also noted that some members of the Australian community do not have access to Medicare (e.g., refugees, international students). These people may experience additional barriers to the use of combination DMARD therapy (including the cost of medical appointments and medications), which may lead to additional health inequity.</p>
                        </div>
                    </div>

                    <div class="etd-domain">
                        <div class="etd-domain-header">
                            <span class="etd-domain-title">Acceptability</span>
                            <span class="etd-rating">Important issues, or potential issues not investigated</span>
                        </div>
                        <div class="etd-domain-text">
                            <p>There is evidence to suggest variation in the use of csDMARDs in combination versus monotherapy as initial therapy for RA. It is likely that this heterogeneity in practice is influenced by several factors, including variation in the preferences of patients and prescribers for the various treatment options. Rheumatologists' beliefs regarding the effectiveness of triple therapy have been shown to vary considerably and to impact on their interpretation of the evidence base and choice of treatment options.</p>
                            <p>A study that compared RA treatment recommendations developed by separate panels comprised of either consumers or clinicians found that when presented with the same data regarding the benefits and harms of triple therapy versus methotrexate monotherapy in DMARD-naïve RA, the consumer panel conditionally favoured triple therapy whereas the clinician panel conditionally favoured MTX monotherapy.</p>
                            <p>A discrete choice experiment that asked patients with early RA to choose between hypothetical treatment options estimated that, after weighing network meta-analysis data on benefits and harms in addition to other considerations including dosing, the majority of patients (78%) would prefer triple therapy over MTX monotherapy as the initial treatment for RA.</p>
                            <p>The consumer panellist noted that many people who have been recently diagnosed with RA are anxious about commencing MTX and that, in comparison, the additional burden of combination therapies in addition to MTX is often considered to be relatively minor.</p>
                        </div>
                    </div>

                    <div class="etd-domain">
                        <div class="etd-domain-header">
                            <span class="etd-domain-title">Feasibility</span>
                            <span class="etd-rating">Important issues, or potential issues not investigated</span>
                        </div>
                        <div class="etd-domain-text">
                            <p>Initial treatment of rheumatoid arthritis with methotrexate alone or in combination with other csDMARDs is consistent with current practice in Australia and there are unlikely to be important feasibility implications. Use of b/tsDMARDs as part of an initial treatment combination in DMARD-naïve patients does not meet current subsidised funding criteria in Australia and therefore would not be feasible to widely implement. As a result of this dichotomy, the panel voted in favour of 'important issues or potential issues not investigated'.</p>
                        </div>
                    </div>
                </div>

                <!-- Practical Info Tab -->
                <div class="tab-content" id="initial-dmard-practical">
                    <div class="content-section">
                        <p>A treat-to-target approach is recommended for all patients with RA, irrespective of the choice of initial treatment regimen.</p>
                        
                        <ul>
                            <li>Any decision regarding the choice of disease-modifying therapy should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual's circumstances</li>
                            <li>Based on data from the network meta-analysis, the probability of achieving an ACR50 response with MTX monotherapy is about 41%; this increases to 56-67% with the use of initial combination therapy (either triple therapy or MTX plus most b/tsDMARDs). Individual patients may vary in their preference for the higher probability of ACR50 versus the increased medication burden</li>
                        </ul>

                        <h4>Other factors that may be important in the choice of initial DMARD therapy include:</h4>
                        <ul>
                            <li>The patient's individual preferences and treatment goals</li>
                            <li>Disease activity and prognosis</li>
                            <li>Comorbidity/ies</li>
                            <li>Concurrent medications</li>
                            <li>Impact of RA on daily activities</li>
                            <li>Impact of RA on work and other life roles</li>
                        </ul>

                        <p>The full text of the network meta-analysis that forms the evidence base for this recommendation may be found <a href="#">here</a>.</p>

                        <h4>Patient Information Resources</h4>
                        <p>The Australian Rheumatology Association provides patient information sheets for those commencing DMARDs, including the following:</p>
                        <ul>
                            <li><a href="#">Methotrexate</a></li>
                            <li><a href="#">Sulfasalazine</a></li>
                            <li><a href="#">Hydroxychloroquine</a></li>
                            <li><a href="#">Leflunomide</a></li>
                        </ul>
                    </div>
                </div>

                <!-- Data Tab -->
                <div class="tab-content" id="initial-dmard-data">
                    <div class="data-placeholder">
                        <p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p>
                    </div>
                </div>

                <!-- For Consumers Tab -->
                <div class="tab-content" id="initial-dmard-consumer">
                    <div class="data-placeholder">
                        <p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <span class="card-updated">Last updated: December 2024</span>
                <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">
                    View in MAGICapp
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg>
                </a>
            </div>
        </div>
    </div>

    <!-- MODAL: Placeholder for other recommendations -->
    <div class="modal-overlay" id="modal-placeholder">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Recommendation</div>
                    <h2 class="modal-title">Content coming soon</h2>
                </div>
                <button class="modal-close" onclick="closeModal()">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg>
                </button>
            </div>
            <div class="modal-body">
                <div class="data-placeholder">
                    <p>📝 Full content for this recommendation will be added soon.</p>
                    <p style="margin-top: 12px;">In the meantime, you can view the complete recommendation in MAGICapp.</p>
                </div>
            </div>
            <div class="modal-footer">
                <span class="card-updated">Coming soon</span>
                <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">
                    View in MAGICapp
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg>
                </a>
            </div>
        </div>
    </div>

    <script>
        // Tab filtering for conditions
        document.querySelectorAll('.condition-tab').forEach(tab => {
            tab.addEventListener('click', () => {
                document.querySelectorAll('.condition-tab').forEach(t => t.classList.remove('active'));
                tab.classList.add('active');
                const condition = tab.dataset.condition;
                document.querySelectorAll('.recommendation-card').forEach(card => {
                    if (condition === 'all') {
                        card.style.display = 'block';
                    } else {
                        card.style.display = card.dataset.conditions.includes(condition) ? 'block' : 'none';
                    }
                });
            });
        });

        // Modal functions
        function openModal(modalId) {
            document.getElementById('modal-' + modalId).classList.add('active');
            document.body.style.overflow = 'hidden';
        }
        
        function closeModal() {
            document.querySelectorAll('.modal-overlay').forEach(modal => {
                modal.classList.remove('active');
            });
            document.body.style.overflow = '';
        }
        
        function switchTab(modalId, tabId) {
            // Update tab buttons within this modal
            const modal = document.getElementById('modal-' + modalId);
            modal.querySelectorAll('.modal-tab').forEach(tab => {
                tab.classList.toggle('active', tab.dataset.tab === tabId);
            });
            
            // Update tab content within this modal
            modal.querySelectorAll('.tab-content').forEach(content => {
                content.classList.remove('active');
            });
            document.getElementById(modalId + '-' + tabId).classList.add('active');
        }
        
        // Close modal on overlay click
        document.querySelectorAll('.modal-overlay').forEach(modal => {
            modal.addEventListener('click', e => {
                if (e.target === modal) closeModal();
            });
        });
        
        // Close modal on escape key
        document.addEventListener('keydown', e => {
            if (e.key === 'Escape') closeModal();
        });
        
        // Smooth scroll for anchor links
        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function(e) {
                e.preventDefault();
                const target = document.querySelector(this.getAttribute('href'));
                if (target) target.scrollIntoView({ behavior: 'smooth', block: 'start' });
            });
        });
    </script>
</body>
</html>
